FDA Delay Causes EpiCept Shares See Red (EPCT, CPIX)

Yet another case of share prices going southbound due to FDA delays! Earlier, Cumberland Pharmaceutical’s

shares tumbled almost 9% due to FDA delaying their decision on CPIX’s drug Acetadote. Now, EpiCept Corporation’s

shares took a nosedive, sinking by more than 39% to $0.65. This came on the back of regulators refusing to accept the company's market application for the drug Ceplene due to questions about the product's effectiveness. EpiCept has been with talks with FDA officials and regulators in a bid to try and get FDA to approve Ceplene to be used in combination with the cancer-fighting agent interleukin-2, or IL-2, to help prevent the recurrence of acute myeloid leukemia. According to EPCT executives, the FDA has “recommended” the company to perform “additional” clinical trials to test the efficacy of Ceplene. EPCT is trading at $0.65, down 40.07% at 11:45 AM EST. CPIX is trading at %5.51, down 8.47%. Analyze Any Stock FREE! Click